Kevin retweeted
$PRME Danaher just put prime editing and base editing on the shelf.
IDT + Aldevron, Nov 4:
• PE Ultra prime editor mRNA, chemically modified Alt-R pegRNAs, and a pegRNA design tool
• Six stocked ABE8e base editors, plus a kit to screen all six at once
• 20 µg to 1 mg in stock, larger runs custom
Research grade. No CGMP timeline announced.
What it replaces: sourcing a plasmid, making your own mRNA, and working out guide design by trial and error.
Stocked inventory is a forecast.
Danaher builds those with a spreadsheet, not a press release.
Same two companies manufactured the components for the world's first mRNA-based personalized CRISPR therapy.
Every target proven in an animal needs a human therapeutic license to go further.
Kevin retweeted
Arrowhead Pharmaceuticals ($ARWR) is the weirdest company in the world. 🧬
In 2011, they bought a $1 billion tech portfolio for "pennies" while drinking pints in a London pub.
Now, they are silencing genes to save lives.
Here is the story of the ultimate Biotech Renaissance. 🧵
#BioTech #ARWR #Investing #Genomics
1/11
Kevin retweeted
4/ Yesterday Capstan Broke the Trend
AbbVie paid $2.1B for Capstan’s in-vivo CAR-T at Phase 1.
That’s 10–15x the typical single-asset price tag.
Why?
Because Capstan isn’t a product.
It’s a platform.
fiercebiotech.com/biotech/ab…
Kevin retweeted
Dr. Pieter Cullis is changing the world, one tiny lipid nanoparticle at a time!
cihr-irsc.gc.ca/e/54321.html…

ALT Side-by-side "How it started / How it's going" meme. Left image (How it started): A black-and-white photo of a Dr. Cullis in the 1980s sitting at a desk using an old computer. The caption below reads: “Assembling lab gear in a coworker’s garage and offering free beer to staff on Fridays.” Right image (How it’s going): A recent photo of Dr. Cullis smiling in a modern lab. The caption below reads: “12 biotech companies. 100+ patents. Millions of lives saved by mRNA technology!"
Kevin retweeted
Interesting comments on extrahepatic targeting of LNPs from a pioneer in the field.
𝐅𝐫𝐨𝐦 𝐕𝐚𝐧𝐜𝐨𝐮𝐯𝐞𝐫: Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery.
Full video: biotechtv.com/post/nanovatio…
Kevin retweeted
$ARWR some preclinical results of ARO-ALK7 (silencing with #Tirzepatide from $LLY). Investors need patience, but the opportunities for the #RNAi play in the obesity market are great in the long term. ir.arrowheadpharma.com/stati…
Kevin retweeted
$ARWR:
I bought $ARWR because I wanted more late stage companies with multiple drugs and multiple indications that could offer a lot of potential.
I bought because the valuation was way below my estimates
I bought because they have 2 later stage programs in cholesterol which are very competitive spaces. I am hopeful they can compete with other therapies in this space.
I bought because they have 2 early obesity programs that could be huge if they are successful. They offer the option of the upside at a much better valuation than other companies in this space that are over hyped.
I bought because they seem to have a sound management team and a good balance sheet.
I bought because I can buy more cheaper if the sector crashes, but I could also sell for big profits if the sector rallies. I like that I am not married to the company so I can be flexible if my strategy changes.
Kevin retweeted
Big opportunity for a Duchenne gene therapy that actually works!
$SRPT CEO says demand for their gene therapy is overwhelming. Haven’t even dosed 5% of eligible patients.
Kevin retweeted
So wonderful to see Tim Harris’ book on biotech arrive from Amazon today!
This is a MUST read for anyone interested in the history of biotech!
Enjoy!!!
Kevin retweeted
The saga is finally over for $SAVA.
Kevin retweeted
Click below for our recent work (preprint) w @AnnaBlakney and Dr. Pieter Cullis. The unofficial cute fun title is “Unbearable heaviness: you may not want to load too many copies of mRNA in one LNP”
chemrxiv.org/engage/chemrxiv…
Kevin retweeted
$TGTX MW has 2 targets
1. $6B mc $40.16 ps
for 1.08M share bonus in 2024
2. $10B mc approx $70 ps
for $16.7M bonus by 2026
On top of the 12M shares he currently owns, can see why he hasn’t raised and would “personally finance TGTX if needed”
Kevin retweeted
There have been vague whispers of bid interest for $TGTX from AstraZeneca, GSK and Novartis although the hot money is on a move from Roche at upwards of $60 a share. Banks including JP Morgan and Goldman Sachs are rumoured to be involved....
Kevin retweeted
$ALNY $ARWR $RNA $DYN $SLN The #RNAi renaissance is just getting started. BPs not embracing and pivoting into this area will regret it.
An RNAi renaissance is creating a new generation of startups…
“There’s an opportunity to create a whole new generation of RNAi therapeutics” biopharmadive.com/news/rnai-…
Kevin retweeted
FACT OR FICTION?
LNP DELIVERY BEYOND LIVER
Has the biotech world quietly solved one of the biggest limitations of LNPs? Is delivery beyond the liver ready for prime time?
Like if true; comment if false
Kevin retweeted
From Peter Cullis ("Father of LNP") - wrote an awesome review on reflecting history of LNP development nature.com/articles/s41573-0…
Kevin retweeted
Our 2024 Annual Meeting & Exposition Starts Today!
At #CRS2024, we look forward to another exciting and innovative event where we celebrate delivery science and technology by sharing scientific knowledge and learning new technologies with colleagues from around the world.
Kevin retweeted
#CRISPR I attended #CRISPRmedicine24, so you don't have to :)
My key take-homes (uncontroversial conference consensus):
1) off-targeting, off-targeting...not solved
2) base editing with less off-targeting, but translocations and on-target indels surprisingly prevalent; no grip on assessing gRNA-independent base editing
3) great progress in HDR (homologous recombination) with efficiencies in 60%+ in presence of NHEJ inhibitors; drawback: increase in translocations
4) enormous focus on HSC-based applications (or do HSC people just speak the loudest?)
5) delivery: adoption of small Cas proteins
6) regulatory advice: focus on unmet medical needs to justify intervention
$NTLA $BEAM $PRME $CRSP






























